Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Amgen | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Amgen

Repatha sales climb 151% to $123 million in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Amgen
1Q Revenues: $5.6 billion(+2%)
1Q Earnings: $2.3 billion (+12%)
Comments: New and recently launched products performed well in the quarter. Repatha sales were up 151% to $123 million driven primarily by higher unit demand. KYPROLIS sales increased 17% to $222 million. Prolia sales increased 16% to $494 million. XGEVA sales increased 11% to $445 million. Sensipar/Mimpara sales increased 18% to $497 million. BLINCYTO sales increased 44% to $49 million. NEUPOGEN sales continued to decline, down 30% to $103 million due to increased competition. EPOGEN and Aranesp sales were also down 10% and 11% to $244 million and $454 million, respectively.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters